• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: COOK IRELAND LTD ZILVER PTX 35 DRUG-ELUTING STENT; NIU STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

COOK IRELAND LTD ZILVER PTX 35 DRUG-ELUTING STENT; NIU STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING Back to Search Results
Catalog Number UNKNOWN
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Ischemia (1942); Insufficient Information (4580)
Event Type  Injury  
Manufacturer Narrative
Pma/510(k) #p100022/s001.Investigation is still pending, a follow up mdr will be submitted to include the investigation conclusions.
 
Event Description
The long-term clinical performance of the zilver ptx stent for femoropopliteal lesions is unclear.A single-center retrospective study was conducted on 101 limbs of 83 patients with zilver ptx stents placed between (b)(6) 2012 and (b)(6) 2013.Target lesion revascularization avoidance rate (ff-tlr) 10 years after treatment, major adverse limb event avoidance rate (ff-male), and major amputation-free survival rate (afs) were the endpoints.Ff-tlr, ff-male, and afs were 60%, 54%, and 57%.Long-term clinical results were reasonable.This file will capture 43% of 83 patients were affected by amputation = 36 patients/devices.
 
Event Description
Supplemental report is being submitted due to the completion of the investigation on 06-dec-2023.
 
Manufacturer Narrative
Pma/510(k) # p100022/s027 device evaluation the zilver ptx drug-eluting peripheral stent devices of rpn and lot numbers unknown involved in this complaint were implanted in the patients and were not available for evaluation.With the information provided, a document-based investigation was conducted.This complaint is related to (b)(4) and (b)(4) and was raised from a single-center retrospective study that was conducted on 101 limbs of 83 patients with zilver ptx stents placed between (b)(6) 2012 and (b)(6) 2013.This complaint will capture 43% of 83 patients were affected by amputation = 36 patients/devices the device evaluation could not be completed as the device, or photographic evidence of the device, was not returned for evaluation.With the information provided, a document-based investigation was conducted.Manufacturing records prior to distribution all zilver ptx drug-eluting peripheral stent devices are subjected to a visual inspection and functional inspection to ensure device integrity.Manufacturing records review could not be completed as the lot number is unknown.Historical data review historical data was not reviewed as the lot number is unknown.Ifu/label review the japanese packaging insert c-ci1502m06 supplied with the device complies with mhlw law no.84 of 2013 which avoids including information that is not specific to the medical device or that which is basic knowledge already understood by the healthcare professional, to ensure to accurately convey all the information that is important for the user.This lists ischemia requiring intervention (bypass or amputation of toe, foot, or leg) as a potential adverse event.There is no evidence to suggest the user did not follow the japanese packaging insert.Image review an image was not returned for evaluation.Root cause review a definitive root cause could not be determined.A possible root cause could have likely been attributed to patients¿ pre existing conditions.From the information available, it is known that the study was to determine the clinical performance of the zilver ptx device on patients with femoropopliteal lesions.As previously noted, ischemia requiring intervention (bypass or amputation of toe, foot, or leg) is listed as a potential adverse event in the japanese packaging insert.Confirmation of complaint the complaint is confirmed based on customer and/or rep testimony.Summary according to the initial reporter, the long-term clinical performance of the zilver ptx stent for femoropopliteal lesions is unclear.A single-center retrospective study was conducted on 101 limbs of 83 patients with zilver ptx stents placed between july 2012 and april 2013.Confirmed quantity of 36 devices, confirmed used.According to the initial reporter, amputation occurred in 36 patients over the 10 year period of the study.Long-term clinical results were reasonable investigation findings conclude a possible root cause could have likely been attributed to patients¿ pre existing conditions as it is known that the patients had femoropopliteal lesions.Complaints of this nature will continue to be monitored for potential emerging trends.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ZILVER PTX 35 DRUG-ELUTING STENT
Type of Device
NIU STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING
Manufacturer (Section D)
COOK IRELAND LTD
o halloran road
limerick
Manufacturer (Section G)
COOK IRELAND LTD
o halloran road
national technology park
limerick
Manufacturer Contact
sinead o'leary
o halloran road
national technology park
limerick 
MDR Report Key17204572
MDR Text Key317919306
Report Number3001845648-2023-00501
Device Sequence Number1
Product Code NIU
Combination Product (y/n)Y
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Health Professional,User Facility,Company Representative
Reporter Occupation Other
Type of Report Initial,Followup
Report Date 12/06/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received06/26/2023
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Catalogue NumberUNKNOWN
Device Lot NumberUNKNOWN
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? No
Was the Report Sent to FDA? No
Event Location Hospital
Date Manufacturer Received05/25/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
-
-